Brands
Spa-ce to grow as Meghavi Wellness bags fastest-growing company title
MUMBAI: When wellness becomes a way of life and not just a weekend indulgence, it’s bound to turn heads. And Meghavi Wellness Spa has clearly been doing just that. The premium spa chain has just clinched the coveted ‘Fastest Growing Indian Company Excellence Award’ at the International Achievers Conference (IAC), held in New Delhi on 31 May 2025. The award was presented by minister of state for social justice & empowerment Ramdas Athawale, during a national seminar themed around “Individual Achievements & National Development – Atmanirbhar Bharat.”
With a wellness footprint that’s rapidly expanding across metro and Tier-2 cities, Meghavi Wellness is redefining what a spa experience feels like in modern India. Think Ayurvedic tradition meets scientific precision with just the right dose of luxe. From ancient healing techniques to high-end tech-backed therapies, the brand is creating what it calls “accessible luxury” in the self-care space.
“This honour is more than an award, it’s a reflection of our belief that wellness has the power to transform lives,” said Meghavi Wellness co-founders Megha Dinesh and Prashant Jain. “We’re building a brand that puts empathy and authenticity at the heart of self-care.”
The award couldn’t come at a better time. With India’s wellness economy booming fuelled by a growing appetite for preventive health, holistic treatments and lifestyle-driven care Meghavi Wellness is tapping into a sweet spot between ancient wisdom and modern well-being. And judging by the speed of its growth, they’re getting the formula just right.
As it sets its sights on new cities, upgraded offerings, and deeper customer engagement, this recognition isn’t just a feather in its cap, it’s a clear marker that Meghavi’s mindful march to the top has only just begun.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
